Results: Twenty-eight (28) patients (13 boys and 15 girls) were included in this study. The mean age of onset was 8.7 years old. The most common presentations were fever (100%), arthritis (89.3%), and skin rash (67.9%). The patterns of arthritis in affected patients were 50% oligoarticular type and 39% polyarticular type. The most common joints involved were the knee (76% of patients with arthritis), ankle (56%), and elbow and proximal interphalangeal joints (28%). The most common pattern of fever during first week was intermittent (53% 
Introduction
Juvenile idiopathic arthritis (JIA), also known as juvenile rheumatoid arthritis or juvenile chronic arthritis, is the most common rheumatic disease in children. 1 JIA is defined as persistent arthritis for !6 weeks if certain exclusionary conditions have been eliminated. 2 The disease onset subtype is defined by clinical symptoms in the first 6 months of the disease.
In 1897, Still outlined his observations on 12 children with systemic juvenile idiopathic arthritis. 3 Since then, systemic-onset juvenile idiopathic arthritis (SoJIA) has been defined as a subtype of JIA and characterized by 6 weeks of arthritis accompanied by intermittent fever daily or twice daily for at least 2 weeks in children aged <16 years in the absence of an identifiable underlying etiology. 4 By the newer International League of Associations for Rheumatology (ILAR) criteria, SoJIA is now more strictly defined as daily quotidian fever of !39
C and requires the presence of at least one of following clinical features of systemic inflammation: characteristic evanescent erythematous skin rash; generalized lymphadenopathy; hepato-splenomegaly; and serositis. 5 The clinical manifestations of SoJIA have little similarity to those of the other JIA subtypes. Unlike other JIA patients whose joint manifestations are more prominent than their general symptoms, the prominent clinical features that distinguish SoJIA are extra-articular manifestations such as fever, rash, and lymphadenopathy. It is usually characterized by laboratory evidence of inflammation, including granulocytosis, thrombocytosis, and the up-regulation of acute phase reactants, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Secondary macrophage activation syndrome (MAS) is a well-known complication most often seen in children with SoJIA.
SoJIA accounts for 10% to 30% of children with JIA and is the most common JIA subtype in hospitalized children. 6 The wide variation of signs and symptoms make diagnosis difficult. Thus, the diagnosis of SoJIA on disease onset is challenging and made mainly by exclusion. This retrospective study aimed to summarize the initial clinical and laboratory features, and clinical course of SoJIA children in a single tertiary care referral centre in Taiwan.
Patients and methods
Patients newly diagnosed with SoJIA at the National Taiwan University Hospital between 1997 and 2007 were identified. The diagnosis of SoJIA was based on the International League of Associations for Rheumatology (ILAR) criteria. 5 All these patients were admitted for evaluation and management, and did not receive any specific treatment for SoJIA before admission. Medical records were reviewed retrospectively and data from the first consult with rheumatologist were collected. The initial symptoms on presentation during the first 2 weeks with regard to fever were recorded and analyzed. Medical records of the followup period up to the end of 2008 were retrospectively examined. Informed consents were obtained before laboratory examination of each patient. The study was approved by the ethics review boards (No. 200905019R).
Since all patients essentially developed daily quotidian fever for at least 2 weeks, the fever pattern during the first week was analyzed and intermittent fever was defined as regular periodic fever lasting >1 day, while continuous fever was defined as an unremitting fever on presentation. The location and number of involved joints at the time of diagnosis were recorded. The oligoarticular type was defined as fewer than four joints in the first 6 months of the disease, while involvement of more than five joints was defined as the polyarticular type.
In order to summarize the therapeutic response, these patients were classified into three groups by the clinical course. Clinical remission course was defined as the absence of active arthritis and systemic features for at least 2 consecutive months and complete discontinuation of medications for >2 months, and without relapse of symptoms and restart of medications. Drug-dependent course was defined as without clinical remission after the onset, or one clinical remission but without complete cessation of medications for >2 months. Relapse course was defined as clinical remission and complete discontinuation of medications for >2 months, but relapse of symptoms and restart of medications.
Laboratory records
Laboratory data, including: complete blood cell count; complements C3 and C4; erythrocyte sedimentation rate (ESR); C-reactive protein (CRP); serum concentrations of immunoglobulins IgG, IgA and IgM; liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT); iron profile (iron, total iron binding capacity, and ferritin); and lactic dehydrogenase (LDH) at the time of diagnosis were gathered, mainly within the first 2 weeks of symptom onset. The status of anti-nuclear antibody (ANA), rheumatoid factor (RF), and human leukocyte antigen B27 (HLA-B27) were also collected.
Statistical analysis
Comparisons of various laboratory values were done using the Mann-Whitney test, Student's t test, and c 2 test accordingly. Inferential statistics with binary logistic regression were used to compare features of patients with and without steroid use for >6 months. A p value <0.05 was considered statistically significant.
Results

Basic profile and clinical manifestations on presentation
Twenty-eight patients, including 13 boys and 15 girls, were enrolled. The mean follow-up period was 69 months. The mean hospitalized stay was 15.8 days. The mean age at onset was 8.7 years (range 1.3e15 years; median 7 years; Fig. 1 ). Among the symptoms on initial presentation, the most common were fever (100%), arthritis (89.3%), and skin rash (67.9%; Fig. 2 The patterns of arthritis (Fig. 3A) were oligoarticular (50%) and polyarticular type (39%). Interestingly, 11% of SoJIA patients did not present with arthritis on disease onset. Of these 3 patients, the mean period from the first day of clinical symptoms to that of developing arthritis was 75 days (62 days, 80 days, and 83 days respectively), and the patterns of arthritis were all oligoarticular type. The mean number of joints involved was 7 (range 0e37). Regarding location of the arthritis, the most common joints involved were the knee (76%), ankle (56%), and elbow and proximal interphalangeal (PIP) joints (28%), followed by the wrist (24%). Arthritis of small joints of the foot was found in only two patients (8%; Fig. 3B ).
All of the patients had fever on presentation. The most common fever pattern during the first week was intermittent (53%), while 18% had daily evening fever. The other fever patterns were split equally among daily morning fever, twice-daily fever, and continuous unremitting fever (Fig. 3C ).
Laboratory characteristics on presentation
Laboratory data on presentation are summarized in Table 1 . Forty percent of patients had leukocytosis and 64.3% had thrombocytosis. White blood and platelet counts were elevated, with a mean of 14.78 Â 10 9 cells/L and 458.86 Â 10 9 cells/L, respectively, while 35.7% had anemia with mean hemoglobin of 10.12 g/dL. The majority of inflammatory parameters, including ESR, CRP, and C3/C4, were elevated. All patients had elevated CRP level on presentation.
There were elevated liver enzymes: 40.7% had elevated AST, 33.3% had elevated ALT, and 90.9% had elevated LDH. Elevated serum ferritin levels were present in 71.4% of patients, with a mean ferritin level of 3075.5 ng/ml. Only two of 28 (7.14%) patients had positive ANA, two of 25 (8%) patients had positive rheumatoid factor, and all patients had negative HLA-B27.
Hemophagocytosis on presentation
In this study, bone marrow aspirates and biopsies were performed in 26 (93%) patients. Positive hemophagocytosis were present in only three (11.5%) patients. The other bone marrow biopsies revealed reactive bone marrow, presented with erythroid and granulocytic hyperplasia without evidence of hymophagocytosis.
Therapeutic strategies and response to treatment
The combination of nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids is often needed to control the extra-articular features. All of the 28 patients had NSAIDs as their primary anti-inflammatory therapy. However, 25 (89.3%) initially required additional corticosteroids, while 27 patients (96.4%) took other disease-modifying antirheumatic drugs (DMARDs). Eleven patients (39.3%) further received etanercept, a biological agent of TNF-a antagonist. Among patients taking etanercept, six presented with polyarticular pattern, four with oligoarticular pattern, and one patient was initially without articular symptoms.
The corticosteroid treatment was mainly used for the acute phases of the systemic disease or during acute flares. Once the symptoms were controlled, the dose was gradually tapered as much as possible to minimize the side effects. Thus, in order to clarify the predictive factors for a refractory disease course, the patients were classified into two groups according to the period of steroid use (>6 months and <6 months) and were compared by basic profile and laboratory parameters on diagnosis. Only two items, Number of patients Figure 1 The patients' age on disease onset. The onset age of the children in this study is evenly distributed. (Table 2) . After comparing features with inferential statistics using binary logistic regression, corrected by age and sex, WBC count was the only predictive factor for prolonged steroid use >6 months (p Z 0.039, odds ratio Z 1.00013, 95% confidence interval 1.000011e1.0000256).
On the relationship between initial articular pattern and duration of steroid use, prolonged steroid use >6 months was more common in children with polyarticular onset (63.6%) than with oligoarticular onset (42.9%) and without articular involvement on onset (33.3%), although this was not statistically significant (Table 3) .
Clinical course
Eight patients (28.6%) achieved complete remission without needing medication for >2 months after a mean of 3.1 months of medication (range 2e7 months). Seven patients (25%) had drug-dependent courses with chronic persistent arthritis, who did not achieve clinical remission after the onset, or gained clinical remission but could not discontinue medications for >2 months. Thirteen (46.4%) had relapsing courses, characterized by flares of articular or/ and extra-articular symptoms, mainly fever. Among those presenting with unusual symptoms, one patient had a relapse with CNS vasculitis and acute respiratory distress syndrome, another relapsed with serositis and had manifestations of pleural effusion. Three patients underwent bilateral total hip replacement and one additional total knee replacement. Of the three MAS patients, two had relapsing courses and the other had drug-dependent courses, indicating a refractory disease outcome. The clinical course and pattern of articular involvement are summarized in Table 3 . Children with polyarticular onset (63.6%) were more prone to develop frequent systemic flares than those with oligoarticular onset (28.6%), although this was not statistically significant.
Discussion
Systemic onset juvenile idiopathic arthritis is heterogeneous in severity and disease course. In contrast to other JIA subtypes, where joint manifestations are more prominent than general symptoms, SoJIA more often presents with extra-articular features such as fever, rashes, and lymphadenopathy. Furthermore, because the presentation of SoJIA is highly variable, this study intended to characterize the features of initial presentation of SoJIA. Leukocytosis and polyarticular pattern on presentation may indicate a refractory clinical course.
Consistent with the previous studies, SoJIA occurs in children with a peak age of onset between 18 months and 2 years in two UK series, but can occur in children of any age. 7e9 The onset age of the children in this study is evenly distributed. However, there should be more caution in diagnosing SoJIA in children aged <1 year because the incidence is relatively low. In contrast to the other JIA subtypes that are female predominant, the incidence of SoJIA is equal in both sexes among Caucasian populations of Europe and North America, 10, 11 which is the same as the results here. Although the classic pattern of quotidian fever is high spiking fever in the evenings, 12 it is only the second most frequent fever pattern in this study. Instead, intermittent fever is the most common on presentation. Therefore, fever pattern is highly variable and does not necessarily fulfill the criteria of ILAR even though it is universally present at disease onset (Fig. 2) . Similarly, arthritis is common on initial presentation (89.3%), with knee, ankle, elbow, and PIP joints being the most commonly affected. In contrast to previous report where the wrist is the most common joint affected in SoJIA, 9 the wrist is the fourth most common affected joint in this study (24%). However, the incidence is still much higher than pauciarticular JIA, where the wrist is only involved in 4% of patients. 13 The sacroiliac joint is the least joint affected, which is the same result as seen in a previous study. 9 Interestingly, 11% of patients did not have arthritis on initial presentation, indicating that the lack of arthritis during disease onset does not exclude the diagnosis of SoJIA. Uveitis complicates several forms of juvenile idiopathic arthritis (oligoarthritis, rheumatoid factor-negative polyarthritis, psoriatic arthritis, and enthesitis-related arthritis), but is *rare in SoJIA. 1, 14 Central retinal vein occlusion was an extremely rare complication that might be related to thrombosis associated with antiphospholipid antibody, 15 even though there was no similar finding in our patient.
Instead of specific laboratory tests for SoJIA, the characteristic patterns of laboratory abnormalities indicate systemic inflammation, including the up-regulation of ESRs, CRP levels, 16 granulocytosis, and thrombocytosis. In this study, serum ferritin and CRP levels were elevated in most patients, which is compatible with previous reports that described those parameters to be correlated with systemic activity. 17, 18 Elevated ferritin levels may be due to augmented interleukin 1b signaling 9 since IL-1b is increasingly recognized in SoJIA patients and induces ferritin mRNA translation. 19, 20 LDH is not a valuable parameter for differentiating malignancy from systemic inflammation because it is increased in most SoJIA patients. Liver enzymes may be abnormal in more severe cases, and together with leukocytosis, can explain the need for corticosteroids for a longer period. While reviewing charts retrospectively, patients who were HLA-B27 seropositive, which is regarded as an exclusion criterion of SoJIA, were excluded from this study. However, HLA typing may be valuable for predicting joint destruction and severity of systemic manifestation of SoJIA. The statistically significant increase in the incidence of HLA-DR4 and HLA-DR3 was observed in the subgroup of patients with radiological evidence of joint destruction and with severe systemic symptoms persisting or recurring for >2 years in comparison with controls respectively. 21 HLA-DQA1*05 and DRB1*11 were associated with systemic arthritis. The DRB1*11-DQA1*05-DQB1*03 haplotype was also increased in systemic arthritis. 22 Macrophage activation syndrome is a serious complication of SoJIA. Its strongest laboratory discriminators are decreased platelet count, increased AST, leukopenia, and hypofibrinogenemia. 23 Behren et al 9 reported that patients with MAS have lower WBC and ESR than those with a normal bone marrow. In the current study, the number of MAS patients (n Z 3) is too small to allow for statistical comparisons. All three MAS patients needed steroid treatment for >6 months. They presented leukocytosis at disease onset and evolved to cytopenia while MAS developed. Therefore, the effect of cytopenia on the prediction for poor outcome was considered to be independent of our statistical comparison.
The aim of therapy in SoJIA is the suppression of unrestrained systemic and local inflammation in order to achieve disease remission and avoid disease relapse and chronic morbidity. NSAIDs, with corticosteroids, are still the appropriate initial therapy. 24 NSAIDs also remain the major treatment for SoJIA in this study. Nevertheless, in the last decade, there have been many therapeutic advances in terms of treatment. Aside from extended use of corticosteroids and methotrexate, there is a trend for the early introduction of other DMARDs.
25e27 Recently, the availability of newer biologic agents, such as anti-TNF-alpha agents, 28, 29 anakinra (an interleukin-1 receptor antagonist), 30, 31 and tocilizumab (an anti-interleukin-6-receptor monoclonal antibody), 32 has provided additional options for refractory cases, although these have not yet been proven consistently effective. In this study, 89.3% of the patients received corticosteroids for controlling acute symptoms. DMARDs are introduced early in the disease course in most of these patients, while etanercept is applied for some patients, mostly those with a polyarticular pattern at onset. Proper and early application of these agents may prevent morbidity related to long-term corticosteroids use. Considerable improvement in the prognosis of SoJIA is attributed to this progress in therapy.
The clinical course and outcomes of SoJIA are highly variable. The previous study reports that about 20% to 30% of children with SoJIA develop destructive polyarthritis with long-term morbidity and disability. 33, 34 However, prognosis is highly variable among previous reports in Taiwan. Lin et al 17 reported that 43% (9/21) of children with SoJIA had chronic polyarthritis with duration >6 months, five of whom had progressive articular damage leading to disability. In contrast, Wang et al 35 showed that none of 12 children with Still's disease developed destructive arthritis. It was consistent with the current study that only three patients developed chronic disability and needed total joint replacement.
About 50% of SoJIA patients have persistent disease activity or remitting flares, or depend on high-dose steroids. 29, 36 Some studies show that steroid dependence and the associated morbidity occur in nearly one-third of patients. 12, 34, 37 In this study, 50% of patients were dependent on steroids for >6 months. Eventually, 28.6% of patients developed a monocyclic pattern with complete remission, 46.4% children had acute flares, and 25% developed drug-dependent persistent arthritis. Lomater et al 34 reported that among patients with SoJIA, the frequency of remission was 100% in those with a monocyclic course, 37% in those with intermittent course, and 23% in those with persistently active course. In Taiwan, Lin et al 17 reported that 71% of patients had monocyclic pattern, while Hsu et al 38 showed that 44% of 16 SoJIA children had clinical remission without relapse, 19% had relapse, and 37% became drug-dependent.
Some studies have clarified the predictive factors for the prognosis of SoJIA. Polyarticular pattern with hip involvement at 6 months predicts a high articular index at 3 years after onset. 16 The presence of active systemic disease at 6 months, as characterized by fever or the need for corticosteroids, and thrombocytosis are strongly correlated with a high CHAQ score at a minimum of 2 years after onset, and predicts poor functional outcome. 37 Schneider et al 33 described that the development of destructive changes within 2 years after disease onset is associated with persistent systemic features and thrombocytosis at 6 months. The current study reports that leukocytosis and polyarticular pattern at onset may indicate a refractory clinical course, may require corticosteroids for more than 6 months, and have higher relapse rate. Leukocytosis on diagnosis suggests a more severe inflammation and polyarticular involvement implies broad extension of disease severity, which may explain the longer duration of treatment and higher rate of flares. Thus, common predictors of poor outcome in SoJIA are associated with greater severity and extension of arthritis at onset, together with prolonged active disease. Adult-onset Still's disease (AOSD) is an inflammatory multisystemic disorder characterized by high spiking fever, evanescent rash, arthralgia or arthritis, sore throat, lymphadenopathy, hepatosplenomegaly, and laboratory abnormalities including neutrophilic leukocytosis, abnormal liver function tests, and increase in acute phase reactants and serum ferritin. 39 There are some possible differences in the clinical characteristics between SoJIA and AOSD. In Taiwan, Chen et al 40 reported that the most common clinical manifestations of AOSD were fever (100%), articular symptoms (100%), evanescent rash (87%), and sore throat (84%). However, among articular symptoms of AOSD, the incidence of arthritis was only 76%, which was lower than that of the children population. Otherwise, the incidence of thrombocytosis was higher and the incidences of sore throat and myalgia were lower in children from this study and Lin et al's study, 17 compared to Chen et al's study. 40 The disease course and outcome were similar between SoJIA and AOSD, where the polycyclic systemic course was the most common (45%), followed by monocyclic systemic course (34%), and only 20% of patients progressed to chronic arthropathy.
This study has some limitations, including its retrospective nature and limited patient numbers because of the hospital-based population. The positive rheumatoid factors have not been confirmed at least 3 months after the first test. The family histories were not all specifically excluded due to insufficient data. The limited numbers also decreased the strength of analysis. However, the study has been able to demonstrate the gross manifestations and therapy of SoJIA, as well as the risk factors associated with therapeutic response and flares. There has been only one recent report 17 about SoJIA among children in Taiwan, and no report regarding the predictors for clinical course in a Taiwanese population.
Conclusion
The clinical manifestations of SoJIA are different from those of the other JIA subtypes. Its major initial features are fever, arthritis, and skin rash, and a significant portion (11%) of patients do not present with arthritis initially. Leukocytosis and polyarticular pattern on presentation indicate a refractory clinical course with longer steroid use and higher rate of flares. The findings here may provide valuable information for clinicians in decision-making for the diagnosis and management of SoJIA.
